| 2023年年报 | 2023年三季报 | 2022年年报 | 2022年三季报 | |
|---|---|---|---|---|
| 营业收入(元) | ||||
| 医药商业(元) | 4,441,242,308.55 | 3,903,000,000.00 | 4,914,597,032.73 | 3,682,306,500.00 |
| 医药生产(元) | - | 4,610,000,000.00 | - | 5,252,610,400.00 |
| CMO/CDMO/CRO业务(元) | 25,668,179.00 | - | 64,608,862.41 | - |
| 医药制造(元) | 5,681,871,326.30 | - | 6,721,346,621.64 | - |
| 其他(元) | 8,763,132.04 | 188,000,000.00 | 7,994,863.41 | 5,991,500.00 |
| 营业成本(元) | ||||
| 医药商业(元) | 3,891,823,019.70 | 3,385,000,000.00 | 4,214,502,835.75 | 3,087,127,000.00 |
| 医药生产(元) | - | 1,564,000,000.00 | - | 2,181,435,800.00 |
| CMO/CDMO/CRO业务(元) | 15,207,863.78 | - | 28,719,807.55 | - |
| 医药制造(元) | 2,094,206,689.90 | - | 2,528,586,626.05 | - |
| 其他(元) | 5,053,554.39 | 158,000,000.00 | 7,789,061.16 | 2,918,200.00 |
| 毛利(元) | ||||
| 医药商业(元) | 549,419,288.85 | 518,000,000.00 | 700,094,196.98 | 595,179,500.00 |
| 医药生产(元) | - | 3,046,000,000.00 | - | 3,071,174,600.00 |
| CMO/CDMO/CRO业务(元) | 10,460,315.22 | - | 35,889,054.86 | - |
| 医药制造(元) | 3,587,664,636.40 | - | 4,192,759,995.59 | - |
| 其他(元) | 3,709,577.65 | 30,000,000.00 | 205,802.25 | 3,073,300.00 |
| 毛利率(%) | ||||
| 医药商业(%) | 12.37 | 13.27 | 14.25 | 16.16 |
| 医药生产(%) | - | 66.07 | - | 58.47 |
| CMO/CDMO/CRO业务(%) | 40.75 | - | 55.55 | - |
| 医药制造(%) | 63.14 | - | 62.38 | - |
| 其他(%) | 42.33 | 15.96 | 2.57 | 51.29 |
| 收入构成(%) | ||||
| 医药商业(%) | 43.72 | 44.86 | 41.97 | 41.18 |
| 医药生产(%) | - | 52.98 | - | 58.75 |
| CMO/CDMO/CRO业务(%) | 0.25 | - | 0.55 | - |
| 医药制造(%) | 55.94 | - | 57.41 | - |
| 其他(%) | 0.09 | 2.16 | 0.07 | 0.07 |
| 毛利构成(%) | ||||
| 医药商业(%) | 13.24 | 14.41 | 14.20 | 16.22 |
| 医药生产(%) | - | 84.75 | - | 83.70 |
| CMO/CDMO/CRO业务(%) | 0.25 | - | 0.73 | - |
| 医药制造(%) | 86.42 | - | 85.06 | - |
| 其他(%) | 0.09 | 0.83 | 0.00 | 0.08 |